India’s major pharmaceutical firms are pivoting toward chronic disease treatments to secure stable, long-term revenue. While this expansion into diabetes and cardiac care drives growth, investors are closely watching the impact on debt levels and return ratios for companies like Mankind Pharma, Alkem, Torrent, and Zydus.
The Indian pharmaceutical landscape is undergoing a structural change as major companies move away from their traditional reliance on acute treatments—such as antibiotics and fever medications—toward long-term chronic care. Medicines for conditions like diabetes, hypertension, and cardiovascular diseases now form a larger part of their portfolios, offering more predictable demand and better pricing power.
Sector Growth and Strategic Shifts
Latest industry data indicates that the chronic care segment is growing faster than the rest of the Indian pharmaceutical market. While the broader market grew by 11.3% in the first half of 2026, the diabetes and cardiac segments outperformed with growth rates of 18.8% and 16.1%, respectively. To capture this, companies are using different playbooks, ranging from large-scale acquisitions to building internal research capabilities.
Financial Trade-offs of Aggressive Expansion
While moving toward chronic care can lead to higher-value product portfolios, it often comes with heavy upfront costs. Mankind Pharma, for example, has aggressively used acquisitions like the ₹13,700 crore purchase of Bharat Serums and Vaccines to build its presence in fertility and critical care. This strategy has increased its debt load, though management has begun repayment, clearing ₹1,250 crore in April 2026. For investors, the challenge remains the compression of its Return on Capital Employed (ROCE), which fell to 14% in FY26, highlighting the pressure of integrating large assets.
Similarly, Torrent Pharmaceuticals has focused on consolidation, notably through the ₹25,700-crore acquisition of JB Pharma. While this has strengthened its market position in hypertension, it pushed the company’s Net Debt to EBITDA ratio to 2.3x. Zydus Lifesciences, meanwhile, has reported strong revenue growth of 17% to ₹27,148 crore in FY26, but its recent spending on acquisitions like Amplitude Surgical has resulted in negative free cash flow, forcing investors to monitor its ability to convert earnings into actual cash.
Organic Growth and Profitability
In contrast to the acquisition-heavy models, Alkem Laboratories has pursued a more organic transformation. By expanding its field force and entering high-growth categories like the GLP-1 (diabetes) market, it has maintained a more stable financial profile. The company reported a 13.5% revenue increase in FY26 with EBITDA margins at 20% and an ROCE of 21%. This approach offers a different risk-reward dynamic for investors compared to those companies utilizing significant leverage for rapid expansion.
As these firms continue to invest in specialty therapies, the primary monitorables for investors will be the successful integration of new businesses, the pace of debt reduction, and whether these companies can restore their return ratios to historical levels. Tracking how well each company manages its cash flow and debt obligations while balancing the costs of new product launches will be essential in the coming quarters.